ERBB2 and breast carcinoma: Similarly, trastuzumab, a mAb against human epidermal growth factor receptor‐2 (HER‐2), was for the first time (1998) clinically approved to treat non‐TNBC HER‐2 positive breast cancer patients having completed chemotherapy [41].